Progress against ALK-positive cancer has always been driven by collaboration.
Every breakthrough, every clinical trial, and every new treatment is made possible because patients, researchers, clinicians, and organizations come together with a shared purpose: improving the lives of people affected by cancer.
That is why we are incredibly honored to be selected as CTI Clinical Trial & Consulting Services’ Q3 Charity of the Quarter through its CTI Cares program.
As a patient-founded and patient-driven organization, ALK Positive exists to accelerate research, expand education, increase access to clinical trials, and ensure the patient voice remains at the center of scientific progress. We know that meaningful partnerships with organizations committed to advancing oncology research help move our mission forward in ways we cannot accomplish alone.
Throughout this quarter, CTI will shine a spotlight on the ALK-positive community through employee engagement, awareness initiatives, charitable giving, and opportunities to share our mission with its global team. More importantly, this partnership represents a shared belief that patients are essential partners in the research process.
We are deeply grateful to everyone at CTI for choosing to support our community and for recognizing the impact that patient advocacy organizations have on the future of cancer research. Their commitment helps raise awareness of ALK-positive cancer while supporting the work our volunteers, researchers, healthcare partners, and community members do every day to improve outcomes for patients around the world.
Together, we are helping accelerate research, strengthen the patient voice, and bring hope to families facing an ALK-positive diagnosis.
Thank you, CTI, for your partnership and for standing with the ALK-positive community. We look forward to the work we’ll accomplish together.
To learn more about this partnership, you can read CTI’s announcement here:
https://www.ctifacts.com/news-events/2026/june/alk-positive-charity
